106 active
/
426 total (since 2015)
23
Phase 1 Active
128 total
37
Phase 2 Active
135 total
33
Phase 3 Active
117 total
22
Phase 4 Active
79 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Neurocrine Biosciences 6 7 3
Luye Pharma Group Ltd. 6 5 0
Bristol-Myers Squibb 4 0 0
Otsuka Pharmaceutical Co., Ltd. 3 2 1
Karuna Therapeutics 2 9 1
Alkermes, Inc. 2 10 0
BioXcel Therapeutics Inc 2 4 0
Intra-Cellular Therapies, Inc. 2 4 0
LB Pharmaceuticals Inc. 2 3 0
Vanda Pharmaceuticals 2 3 0
Vigonvita Life Sciences 2 0 0
Qilu Pharmaceutical Co., Ltd. 2 0 0
Otsuka Pharmaceutical Development & Commercialization, Inc. 1 25 5
AbbVie 1 4 2
Newron Pharmaceuticals SPA 1 2 0
NCT07084831 RECRUITING
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
European Group for Research In Schizophrenia n=171
NCT07288567 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb n=166
NCT07424404 NOT YET RECRUITING
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
Karuna Therapeutics n=400
NCT05304767 RECRUITING
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics n=280
NCT06882785 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Bristol-Myers Squibb n=250
NCT05303064 RECRUITING
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc. n=220
NCT04987229 ENROLLING BY INVITATION
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Alkermes, Inc. n=236
NCT06894212 RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=522
NCT07263022 NOT YET RECRUITING
Cognitive Strategies in Early Psychosis 2
University of Minnesota n=24
NCT06963034 RECRUITING
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences n=284
NCT07184619 RECRUITING
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Newron Pharmaceuticals SPA n=400
NCT07369154 NOT YET RECRUITING
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc. n=900
NCT07363577 NOT YET RECRUITING
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc. n=456
NCT05603104 RECRUITING
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Dr. Inge Winter n=1,254
NCT07225712 RECRUITING
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=100
NCT06961968 RECRUITING
Randomized Withdrawal Study in Patients With Schizophrenia
Vanda Pharmaceuticals n=400
NCT05838573 RECRUITING
Metformin Treatment on Cognitive Impairment of Schizophrenia
Central South University n=120
NCT07045142 RECRUITING
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
Central South University n=400
NCT07227818 NOT YET RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences n=560
NCT07114874 RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences n=800
NCT03817502 RECRUITING
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Gedeon Richter Plc. n=330
NCT06191965 RECRUITING
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Mclean Hospital n=100
NCT07105098 RECRUITING
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences n=284
NCT06229210 RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc. n=500
NCT05325645 RECRUITING
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=450
NCT06799559 NOT YET RECRUITING
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
Qilu Pharmaceutical Co., Ltd. n=402
NCT05184335 RECRUITING
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Reviva Pharmaceuticals n=690
NCT05326347 ACTIVE NOT RECRUITING
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Otsuka Pharmaceutical Co., Ltd. n=190
NCT06649214 NOT YET RECRUITING
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Qilu Pharmaceutical Co., Ltd. n=654
NCT06589817 NOT YET RECRUITING
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
Chengdu Kanghong Pharmaceutical Group Co., Ltd. n=376
NCT06482554 RECRUITING
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Louisiana State University Health Sciences Center Shreveport n=80
NCT06351514 RECRUITING
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Institute of Mental Health, Singapore n=40
NCT03094429 RECRUITING
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
SyneuRx International (Taiwan) Corp n=287
NCT05110157 COMPLETED
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Neurocrine Biosciences n=442
NCT04857983 COMPLETED
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
University of California, San Diego n=62
NCT04860830 COMPLETED
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
Boehringer Ingelheim n=609
NCT03238326 COMPLETED
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=295
NCT05693935 COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
Teva Branded Pharmaceutical Products R&D LLC n=675
NCT04115319 COMPLETED
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Otsuka Pharmaceutical Development & Commercialization, Inc. n=305
NCT05919823 COMPLETED
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Karuna Therapeutics n=202
NCT04846881 COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
Boehringer Ingelheim n=611
NCT05628103 COMPLETED
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
Otsuka Pharmaceutical Development & Commercialization, Inc. n=101
NCT05741528 COMPLETED
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Otsuka Pharmaceutical Development & Commercialization, Inc. n=75
NCT03485417 COMPLETED
Substance Misuse To Psychosis for Stimulants
The University of Hong Kong n=165
NCT04846868 COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
Boehringer Ingelheim n=620
NCT04578756 COMPLETED
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
AbbVie n=310
NCT05368558 TERMINATED
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
AbbVie n=34
NCT05838625 COMPLETED
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. n=464
NCT06067984 COMPLETED
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. n=73
NCT02469155 COMPLETED
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Intra-Cellular Therapies, Inc. n=696
NCT05658510 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
BioXcel Therapeutics Inc n=452
NCT04820309 COMPLETED
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Karuna Therapeutics n=566
NCT03121586 TERMINATED
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
ACADIA Pharmaceuticals Inc. n=995
NCT04531982 COMPLETED
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
ACADIA Pharmaceuticals Inc. n=454
NCT05211947 TERMINATED
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
Boehringer Ingelheim n=1,362
NCT02431702 COMPLETED
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
Janssen Scientific Affairs, LLC n=337
NCT03345342 COMPLETED
A Study of Paliperidone Palmitate 6-Month Formulation
Janssen Research & Development, LLC n=841
NCT04072575 COMPLETED
A Study of Paliperidone Palmitate 6-Month Formulation
Janssen Research & Development, LLC n=178
NCT02713282 COMPLETED
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Janssen-Cilag Ltd. n=306
NCT03874494 COMPLETED
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
Otsuka Beijing Research Institute n=371
NCT03510325 COMPLETED
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
Shanghai Mental Health Center n=762
NCT06878833 WITHDRAWN
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
Lyndra Inc.
NCT06572449 COMPLETED
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
Karuna Therapeutics n=173
NCT05145413 COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Karuna Therapeutics n=396
NCT05359081 TERMINATED
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Sumitomo Pharma Co., Ltd. n=68
NCT04109950 TERMINATED
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=463
NCT04738123 COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Karuna Therapeutics n=256
NCT05654870 TERMINATED
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
Neurocrine Biosciences n=8
NCT04959032 COMPLETED
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Intra-Cellular Therapies, Inc. n=228
NCT04659174 COMPLETED
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
Karuna Therapeutics n=152
NCT05779241 COMPLETED
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Inc. n=83
NCT03437668 TERMINATED
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
Chengappa, K.N. Roy, MD n=47
NCT03201757 COMPLETED
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Alkermes, Inc. n=523
NCT02685748 COMPLETED
Aspirin in Young Psychotic Patients
Clinic for Psychiatric Disorders, Dr Laza Lazarevic n=60
NCT04072354 COMPLETED
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=463
NCT04092686 COMPLETED
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=464
NCT05643170 TERMINATED
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Karuna Therapeutics n=4
NCT03896945 TERMINATED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=136
NCT02261519 TERMINATED
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
SyneuRx International (Taiwan) Corp n=280
NCT04825860 TERMINATED
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
Sumitomo Pharma Co., Ltd. n=83
NCT03198078 COMPLETED
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. n=316
NCT04659161 COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
Karuna Therapeutics n=252
NCT04268303 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
BioXcel Therapeutics Inc n=380
NCT03397134 COMPLETED
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
Minerva Neurosciences n=515
NCT03503318 COMPLETED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc. n=544
NCT03465787 COMPLETED
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
Bukwang Pharmaceutical n=210
NCT03187769 COMPLETED
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
Alkermes, Inc. n=426
NCT03893825 COMPLETED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc. n=336
NCT03788759 COMPLETED
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara n=48
NCT03149107 TERMINATED
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
University Hospital, Bonn n=48
NCT03593213 TERMINATED
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
AbbVie n=587
NCT03870880 COMPLETED
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
Rovi Pharmaceuticals Laboratories n=215
NCT03160521 COMPLETED
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
Rovi Pharmaceuticals Laboratories n=438
NCT04327843 COMPLETED
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
Case Western Reserve University n=22
NCT03043820 COMPLETED
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
Iris Sommer n=110
NCT03892889 TERMINATED
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Otsuka Pharmaceutical Development & Commercialization, Inc. n=277
NCT03955549 COMPLETED
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
Agiad Psychiatry Hospital n=99
NCT02873208 COMPLETED
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes, Inc. n=266
NCT02983188 COMPLETED
Berberine as Adjuvant Treatment for Schizophrenia Patients
The University of Hong Kong n=113
NCT03172871 COMPLETED
Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
Otsuka Beijing Research Institute n=436
NCT02892422 COMPLETED
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
H. Lundbeck A/S n=528
NCT02876900 COMPLETED
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
Noven Pharmaceuticals, Inc. n=617
NCT03345979 COMPLETED
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Alkermes, Inc. n=200
NCT02970292 COMPLETED
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
ACADIA Pharmaceuticals Inc. n=396
NCT03848234 COMPLETED
Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
Tangent Data n=209
NCT02773576 COMPLETED
Safety and Tolerability of Risperidone Implants
Braeburn Pharmaceuticals n=140
NCT02694328 COMPLETED
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Alkermes, Inc. n=561
NCT03230864 TERMINATED
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
H. Lundbeck A/S n=119
NCT02717195 COMPLETED
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
H. Lundbeck A/S n=1,098
NCT02669758 COMPLETED
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes, Inc. n=281
NCT03915938 COMPLETED
Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain
Hospital de Clinicas de Porto Alegre n=24
NCT02194933 COMPLETED
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
Otsuka Pharmaceutical Development & Commercialization, Inc. n=38
NCT02634346 COMPLETED
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Alkermes, Inc. n=403
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT02308956 COMPLETED
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
University of Cape Town n=324
NCT02758067 WITHDRAWN
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
H. Lundbeck A/S
Data: ClinicalTrials.gov